Crucell, Aeras Announce Start of a TB Vaccine Clinical Trial in the US

January 9, 2008
BioPharm International Editors

Crucell NV (Leiden, The Netherlands), has announced that it will receive up to $5 million from the Aeras Global TB Vaccine Foundation (Rockville, MD), to support the development of its AdVac- and PER.C6-based tuberculosis vaccine candidate.

Crucell NV (Leiden, The Netherlands), has announced that it will receive up to $5 million from the Aeras Global TB Vaccine Foundation (Rockville, MD), to support the development of its AdVac- and PER.C6-based tuberculosis vaccine candidate.

Aeras and Crucell began jointly developing this vaccine candidate, called AERAS-402, in 2004 using Crucell’s AdVac vaccine technology and PER.C6 manufacturing technology. A Phase 1 clinical trial launched in October 2006 in the US indicated that the vaccine candidate is safe in healthy adults. A second study, currently in progress in healthy adults in South Africa, appears to be showing safety, tolerability, and immunogenicity of AERAS-402.

The main parameters under examination in the St. Louis study will be the immunogenicity and safety of BCG prime followed by two AERAS-402 boost doses administered at three to six month intervals after BCG in healthy adults.

Crucell release

Related Content:

News